The Food and Drug Administration rejected ivonescimab, a cancer drug invented in China, hindering international expansion efforts for drug developers in the region.
- Summit Therapeutics disclosed the agency’s decision in a news release on Sunday, halting plans to bring the Akeso Biopharma-invented drug to the American market.
- Regulators cited a lack of statistically significant evidence showing the drug prolonged patients’ lives in the global clinical trial.
- The treatment had previously delayed cancer progression when compared against chemotherapy alone in a multi-region study.
The Food and Drug Administration rejected the lung cancer treatment after reviewing data from a clinical trial conducted across the United States, Canada, Europe, and Asia. Summit Therapeutics, based in Florida, had acquired U.S. rights to the medication from China-based Akeso Biopharma. The application sought approval specifically for patients with advanced lung cancer who had already undergone targeted treatment.
Regulators determined the submission fell short because the global trial did not demonstrate a statistically significant benefit in extending overall survival rates. The study tracked patients receiving ivonescimab alongside chemotherapy against a control group receiving chemotherapy alone.
While the drug successfully delayed cancer progression during the international study, regulators focused on overall survival metrics. Company executives maintained that slower enrollment periods across trial sites impacted the longer-term survival outcomes captured in the data.
Seeking to address the gap, representatives submitted additional analyses tracking longer-term patient outcomes that fell outside the original research plan. The supplementary figures failed to persuade agency officials to reverse their stance on the application.
The decision marks a setback for a medication that had become a symbol of China’s ascendance as a powerhouse in drug development. Beyond advanced lung care, researchers have been actively testing the therapy against tumors affecting the colon, bladder, and breast.
Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.